Lopresor 100: Main Uses and Benefits

Lopresor 100 (metoprolol tartrate) is a prescription medicine used to manage conditions related to the cardiovascular system. Its therapeutic use is centered on addressing concerns related to the heart and blood vessels.

The medication is commonly used to treat high blood pressure (hypertension), which can assist in regulating blood pressure levels. The goal is to provide relief from symptoms that may be associated with high blood pressure. It is also utilized for the management of long-term chest pain due to heart disease (angina pectoris) and is applied in the management of patients following a heart attack (myocardial infarction).

Indications for Lopresor 100 include hypertension, angina pectoris, and myocardial infarction.

“Consultation with your healthcare provider is important for the appropriate use of this medication.”

---

Quick Fact: Relief for Chest Pain and High Blood Pressure

Eligibility Profile: Who Can and Cannot Use Lopresor 100?

This eligibility information is based strictly on authoritative government regulatory documents and prescribing information for metoprolol tartrate (Lopresor).

Contraindicated Populations (Must NOT Use)

Condition
Cardiogenic Shock or decompensated heart failure requiring intravenous inotropes.
Known Hypersensitivity to metoprolol, its excipients, or other beta-blockers.
Severe Bradycardia (very slow heart rate, generally below 50 beats/min).
Second- or Third-Degree Atrioventricular Block or Sick Sinus Syndrome (unless a permanent pacemaker is present).
Acute Myocardial Infarction with specific low hemodynamic parameters (e.g., heart rate < 45 beats/min or systolic blood pressure < 100 mmHg).

Conditional or Restricted Use

• Pediatric Use (Children/Adolescents): Use is not recommended as safety and efficacy have not been established in this age group.
• Bronchospastic Disease (e.g., Asthma): Generally avoided; if required, it must be used with caution at the lowest possible dose.
• Pregnancy and Lactation: Use is conditional and only recommended if the therapeutic benefit justifies the potential risk to the fetus or infant. Infants must be monitored for signs of beta-blockade.
• Severe Hepatic Impairment: Requires caution and consideration of dose reduction due to the drug’s metabolism.

Interactions with other medicines and products

The interaction profile of Lopresor 100 (metoprolol tartrate) is formally documented in regulatory sources and defined by specific restrictions, metabolic considerations, and additive pharmacodynamic effects.

Official Prohibitions and Restrictions

A key contraindication exists for the intravenous co-administration of metoprolol with certain calcium channel blockers, specifically Verapamil and Diltiazem. This prohibition is due to the officially documented risk of severe cardiac depression. This restriction is extended to certain other intravenous antiarrhythmics.

Pharmacokinetic and Exposure Effects

Metoprolol is metabolized via the CYP2D6 enzyme system. Co-administration with potent CYP2D6 inhibitors (such as quinidine, fluoxetine, and paroxetine) results in a pharmacokinetic interaction that officially increases the metoprolol plasma concentration, often doubling the systemic exposure. This effect of increased metoprolol concentrations is also documented with Hydralazine, which may inhibit presystemic metabolism. Concomitant use with alcohol is also noted to affect the rate of metoprolol clearance.

Additive Pharmacodynamic Effects

Additive effects on cardiac function are documented with other substance categories. For instance, co-use with Digitalis glycosides or catecholamine-depleting drugs like Reserpine may increase the risk of marked bradycardia or hypotension. A procedural requirement is established for discontinuing Clonidine: metoprolol must be stopped several days prior to the gradual withdrawal of Clonidine to prevent exacerbation of rebound hypertension.

Administration Requirements

Official labeling documents an interaction with food: the immediate-release tablet must be taken with or immediately following a meal to ensure appropriate systemic absorption.

Selective Blocking of beta1 Receptors

Lopresor 100 (metoprolol) works by selectively blocking beta1-adrenergic receptors, which are predominantly located in cardiac tissue. This mechanism involves the drug occupying the receptor sites, thereby preventing the binding of the body's natural signaling molecules, the catecholamines (such as adrenaline). This action constitutes the primary mechanistic step that influences the sympathetic nervous system's signaling to the heart.

---

Modulating Sympathetic Nervous System Activity

By occupying the beta1 receptors, the drug suppresses the downstream signal transduction cascade that normally increases cardiac function. This intervention limits the acceleration and force of the heart muscle's response to neural and humoral stimulation, resulting in decreased signaling within this regulatory pathway.

---

Reduction in Cardiac Workload

The resulting physiological effect of the mechanism is a reduction in both the heart's rate (negative chronotropy) and the force of its contractions (negative inotropy). This pharmacological action leads to a corresponding decrease in the heart's overall energy expenditure and myocardial oxygen consumption, limiting the mechanical activity of the cardiac muscle.

Lopresor 100 (metoprolol tartrate) is an immediate-release oral tablet and its usage is structured around specific official administration guidelines. The medicine is primarily taken via the oral route for long-term cardiovascular management, although an intravenous (IV) formulation is approved for initial, acute intervention in hospital settings for conditions like myocardial infarction, followed by a transition to oral dosing.

Standard Dosage Regimens

The typical adult dosing is determined by the specific condition being addressed. For Hypertension and Angina Pectoris, the usual starting oral dose is 100 mg daily, which may be given as a single dose or in divided doses. Maintenance doses typically range between 100 mg and 450 mg per day. Following the acute phase of a heart attack, the maintenance dose is officially 100 mg orally twice daily.

Administration and Procedural Rules

Timing with Food: A key administration instruction is that the immediate-release tablets must be taken with or immediately following a meal; this procedure enhances the bioavailability and systemic absorption of the metoprolol.

Dose Adjustment: Any modification to the prescribed dose must be performed gradually. Dosage adjustments (titration) are officially recommended at weekly or longer intervals until the desired regimen is achieved. For treatment discontinuation, the dose must be gradually reduced over a period of 1 to 2 weeks to prevent potential procedural complications.

Special Populations: Patients with significant hepatic impairment may require consideration of lower doses due to reduced drug clearance. However, no specific dose adjustment is typically needed for patients with renal impairment.

Lopresor (metoprolol tartrate) is an immediate-release beta-blocker that has been subject to extensive clinical research over several decades, primarily for its role in managing cardiovascular conditions. The key evidence pertains to its use in hypertension, angina pectoris, and post-myocardial infarction care.

Clinical Findings in Cardiovascular Management

Clinical trials have evaluated the effects of metoprolol on several important heart-related outcomes. Early research demonstrated its use as an effective agent for lowering blood pressure in adults with hypertension, both when used alone or in combination with other treatments, such as thiazide-type diuretics. Reductions in blood pressure are associated with a reduced risk of fatal and non-fatal cardiovascular events, including stroke and myocardial infarction.

In studies involving patients with angina pectoris, metoprolol was investigated for its potential to reduce the frequency of angina attacks and influence exercise tolerance. Findings indicate its established use in the long-term management of chronic stable angina.

Post-Myocardial Infarction Research

Following an acute myocardial infarction (MI), clinical trials have supported the use of metoprolol in hemodynamically stable patients. Research has focused on its potential to reduce cardiovascular mortality in this population when administered acutely and continued as oral maintenance therapy. The evidence contributes to its recognized role in post-MI treatment protocols.

Condition	Primary Focus of Research	Key Findings Observed
Hypertension	Blood pressure reduction	Reduction in systolic and diastolic blood pressure.
Angina Pectoris	Symptoms and exertion	Influence on the frequency of angina episodes and physical capacity.
Acute MI	Cardiovascular mortality	Association with reduced mortality in hemodynamically stable patients.

Common questions about Lopresor 100 (FAQ)

Q: What is the fundamental difference between Lopresor (metoprolol tartrate) and metoprolol succinate?

Lopresor is the brand name for metoprolol tartrate, which is an immediate-release (IR) formulation. The other formulation, metoprolol succinate, is an extended-release (ER) version. Official regulatory information states that these two forms are not considered interchangeable.

Q: Can Lopresor 100 potentially lead to changes in body weight?

Official safety documents report that rapid weight gain or other unusual weight fluctuations have been noted as potential adverse effects associated with this medication. This information is based on data collected during clinical use and is included in regulatory documents.

Q: Is decreased libido or sexual side effects associated with Lopresor 100?

Official product information indicates that sexual side effects have been reported in association with the use of Lopresor 100. Specifically, adverse events such as erectile dysfunction (impotence) and changes in libido have been noted in regulatory documents.

Q: Can Lopresor 100 affect vision, such as causing blurry vision or dry eyes?

According to official regulatory information, Lopresor 100 has been associated with effects on vision. Reported adverse reactions include general visual impairment, such as blurred vision, and the symptom of dry eyes.

Q: Can Lopresor 100 cause increased sweating or unusual clamminess?

Official product labeling indicates that increased sweating, clinically termed hyperhidrosis, is a reported adverse reaction associated with this medicine.

Q: What is Raynaud's phenomenon, and is it connected to Lopresor 100 use?

Official regulatory documents list cold hands and feet as a common side effect of this drug. For individuals with existing severe peripheral circulation issues, reported adverse events include conditions like Raynaud's phenomenon.

Q: How long does it usually take for Lopresor 100 to start affecting blood pressure or heart rate?

Official prescribing information states that a significant beta-blocking effect typically begins relatively quickly. This effect, which can be measured by a reduction in heart rate during activity, is observed within about one hour following a dose.

Q: What is the approximate half-life of Lopresor 100 (metoprolol tartrate) in the body?

The mean elimination half-life of the active ingredient in Lopresor 100 is typically three to four hours in the body. However, official pharmacokinetic data indicates that this duration can be longer in certain individuals who metabolize the drug more slowly.

Q: Is it safe to consume alcohol while under treatment with Lopresor 100?

Official regulatory information notes that consuming alcohol while taking Lopresor 100 can influence how quickly the medicine is cleared from the body. This interaction may affect the concentration of the medication in the body.

Q: Is Lopresor 100 safe for use in elderly patients, and are there special considerations?

Official product information indicates that caution is advised when this medicine is used in the elderly population. There is a possibility of an overly pronounced decrease in blood pressure or pulse rate, and regulatory documents mention that considering a lower dose may be appropriate.

Q: Does Lopresor 100 pass into breast milk during breastfeeding?

Studies and official documents confirm that the active ingredient in Lopresor 100 passes into breast milk. For this reason, the use of this medication during breastfeeding is conditional, and infants must be monitored for signs of beta-blockade effects.

Q: Does Lopresor 100 interfere with the body's natural response to low blood sugar (hypoglycemia) symptoms?

Official safety information states that Lopresor 100 may mask certain physical symptoms associated with low blood sugar, or hypoglycemia. This occurs because the drug can dampen the body's usual response, such as a rapid or fast heartbeat, which is an important warning sign.

Q: Does Lopresor 100 have any reported impact on sleep patterns, such as insomnia or nightmares?

According to official regulatory documents, adverse reactions affecting sleep patterns have been reported. These include insomnia (difficulty sleeping) and nightmares or vivid dreams, which are categorized under nervous system or psychiatric disorders.

Q: What are the common gastrointestinal side effects of Lopresor 100, such as diarrhea or constipation?

Official product information lists several gastrointestinal adverse reactions. These commonly reported effects include diarrhea, nausea, dry mouth, and also constipation.

Q: Are there specific activities, like driving or operating machinery, that Lopresor 100 may affect?

Official safety information includes a caution regarding activities that require full alertness, such as driving or operating heavy machinery. This is based on reported side effects that include dizziness, tiredness, and sometimes confusion.

Q: Does Lopresor 100 interact with common over-the-counter pain relievers like NSAIDs?

Official drug guidance sources indicate a potential interaction when Lopresor 100 is taken with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common pain relievers. This combination may potentially work against the medicine's primary effect by causing an increase in blood pressure.

Q: Is there an interaction risk if a patient needs to be treated with epinephrine (adrenaline)?

Official labeling documents a risk of interaction with administered epinephrine (adrenaline), such as the kind used to treat a severe allergic reaction. The information states that patients taking beta-blockers, including Lopresor 100, may be unresponsive to the usual dose of epinephrine.

Q: Is there a need for caution when Lopresor 100 is combined with other central nervous system depressants?

Official information indicates that caution is necessary when Lopresor 100 is used alongside other central nervous system (CNS) depressants. This is due to the potential for metoprolol to cause CNS side effects like dizziness, confusion, and sedation, which could be enhanced by co-administration.

How to Store and Dispose of Lopresor 100?

The official storage and disposal requirements for Lopresor 100 (metoprolol tartrate) tablets are defined by regulatory labeling to ensure product stability and environmental safety.

Official Storage Requirements

Detail	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep away from excess heat and moisture and protected from light.
Container	Store in the container it came in and keep the container tightly closed.
Child Safety	Keep out of the sight and reach of children and pets (P405: Store locked up).

Disposal Instructions

Unused or expired medication must be handled according to official environmental regulations. Patients are directed to consult local medicine take-back programs or waste disposal services. It is strictly required to not throw the product into wastewater or allow it to enter sewers or surface water, in accordance with official environmental precautions.